Your browser doesn't support javascript.
loading
Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
Wang, Ying; Sun, Yalan; Lu, Fang; Zhao, Xianghong; Nie, Zhenlin; Zhu, Feng; He, Bangshun.
Afiliación
  • Wang Y; School of Basic-Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Sun Y; Deparment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China.
  • Lu F; School of Basic-Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Zhao X; Deparment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China.
  • Nie Z; School of Basic-Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Zhu F; Deparment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, Jiangsu, China.
  • He B; School of Basic-Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Clin Transl Oncol ; 26(7): 1725-1737, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38587602
ABSTRACT

PURPOSE:

Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have showed its benefits in clinical studies, and here we conducted a further evaluation on the safety and efficacy of this treatment strategy.

METHODS:

A systematic literature review was conducted in PubMed, Embase and Cochrane Library to identify clinical studies on ICIs and chemotherapy for metastatic breast cancer. The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS), and adverse events (AEs) were analyzed. Random or fixed effects models were used to estimate pooled Hazard ratio (HR), odds ratio (OR) and the data of 95% confidence interval (CI) depend on the Heterogeneity. Cochrane risk assessment tool was used to assess risk of bias. We also drew forest plots and funnel plots, respectively.

RESULTS:

Seven studies with intend-to-treat (ITT) population for 3255 patients were analyzed. ICIs pooled therapy showed clinical benefits compared with chemotherapy alone, improving PFS (HR = 0.81, 95% CI 0.74-0.90) of patients with metastatic triple negative breast cancer (mTNBC), especially in patients with PD-L1-positive tumors. However, it had no effect on OS (HR = 0.92, 95% CI 0.85-1.01). Besides, mTNBC patients received pooled therapy were less frequently to have AEs (OR = 1.30, 95% CI 1.09-1.54). In patients with metastatic Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, pooled therapy showed no benefit for PFS (HR = 0.80, 95% CI 0.50-1.28) and OS (HR = 0.87, 95% CI 0.48-1.58).

CONCLUSION:

Pooled therapy had improved PFS in mTNBC patients, especially in patients with PD-L1-positive tumors, and it was less likely to cause grade ≥ 3 AEs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Puntos de Control Inmunológico Límite: Female / Humans Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Puntos de Control Inmunológico Límite: Female / Humans Idioma: En Revista: Clin Transl Oncol Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Italia